Please provide your email address to receive an email when new articles are posted on . Topline results from the phase 3 ReThink-ALZ study of simufilam in mild to moderate Alzheimer’s disease showed ...
No significant reduction in cognitive or functional decline was observed with simufilam compared with placebo. A phase 3 trial evaluating simufilam for the treatment of Alzheimer disease (AD) did not ...
Cassava Sciences Inc. (NASDAQ:SAVA) on Tuesday shared topline results from the Phase 3 REFOCUS-ALZ study of simufilam in mild-to-moderate Alzheimer’s disease. REFOCUS-ALZ randomized approximately ...
Cassava Sciences Inc SAVA announced topline clinical results from its Cognition Maintenance Study (CMS), a small proof-of-concept study designed to demonstrate the effects of simufilam versus placebo ...
An Independent Data and Safety Monitoring Board (DSMB) Recently Evaluated the Interim Patient Safety Database for Simufilam in On-Going Phase 3 Clinical Trials. The DSMB Recommended the Phase 3 Trials ...
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...
Oral Simufilam Continues to be Safe, Well Tolerated. AUSTIN, Texas, July 05, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company, today announced top-line clinical ...
An interim analysis of the open-label study of simufilam, Cassava Sciences Inc., of Austin, Texas, showed six months’ treatment with the oral, small molecule improved cognition and behavior scores in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results